加载中
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
前收盘价
US$10.51
+US$0.60 · +6.05%
盘中时间采用ET。市场数据可能有所延迟。
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
日内区间
当前US$10.51
52周区间
当前US$10.51
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
44
合理估值
情绪
68
看涨
风险
49
风险偏高
动量
65
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
日内区间
当前US$10.51
52周区间
当前US$10.51
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.13亿 USD | 1474.5万 USD | 62.2万 USD | 24万 USD | 93.4万 USD |
| 销货成本 | 75.3万 USD | — | — | — | — |
| 毛利 | 1.13亿 USD | 1474.5万 USD | 62.2万 USD | 24万 USD | 93.4万 USD |
| 研究与开发 | 2.08亿 USD | 1.9亿 USD | 2.32亿 USD | 2.48亿 USD | 1.96亿 USD |
| 销售、一般及管理费用 | 1.47亿 USD | 1.69亿 USD | 1.3亿 USD | 1.03亿 USD | 1.35亿 USD |
| 营业费用 | 3.69亿 USD | 3.59亿 USD | 3.63亿 USD | 3.52亿 USD | 3.31亿 USD |
| 利息收入 | 669.7万 USD | 240万 USD | 86.3万 USD | 270.8万 USD | 83.6万 USD |
| 利息支出 | 1.13亿 USD | 1.32亿 USD | 8671.7万 USD | 4714.5万 USD | 1484.9万 USD |
| 折旧和摊销 | 1552.5万 USD | 1755.4万 USD | 1851.2万 USD | 1826万 USD | 1423.8万 USD |
| 营业利润 | −2.56亿 USD | −3.44亿 USD | −3.62亿 USD | −3.51亿 USD | −3.3亿 USD |
| 净利润 | −3.51亿 USD | −4.14亿 USD | −5.83亿 USD | −4.17亿 USD | −3.47亿 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.00
上涨空间 14.18%报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1.18亿1.19%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1.01亿0.13%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI9241.11万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB6701.08万0.04%1853亿 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK3837.89万0.08%447亿 USD0.05%US$344.74+1.22%
iShares Russell 2000 Growth ETFIWO3537.59万0.26%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB3020.04万0.29%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Extended Market ETFVXF3001.62万0.03%954亿 USD0.05%US$235+0.80%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
